MAPT and Alzheimer disease: CSF biomarker signature based on low Aβ 1-42 and high T-tau as well as a positive amyloid PET signal qualify to identify patients with clinical diagnosis of mild to moderate AD who are at increased risk to have an underlying AD neuropathology, for the purpose of enriching a clinical trial population.